Resolving ethical issues in stem cell clinical trials: The example of Parkinson disease

Journal of Law, Medicine and Ethics

Volumn 38, Issue 2, 2010, Pages 257-266

  Lo, Bernard ^a   Parham, Lindsay ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

CLINICAL TRIAL (TOPIC); CONFERENCE PAPER; ETHICS; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; GOVERNMENT REGULATION; HUMAN; LEGAL ASPECT; METHODOLOGY; PARKINSON DISEASE; PATIENT ADVOCACY; PATIENT SELECTION; SAFETY; STEM CELL TRANSPLANTATION; UNITED STATES;

CLINICAL TRIALS AS TOPIC; ETHICAL ANALYSIS; ETHICAL REVIEW; FEDERAL GOVERNMENT; GOVERNMENT REGULATION; HUMANS; PARKINSON DISEASE; PATIENT ADVOCACY; PATIENT SELECTION; PLACEBOS; RESEARCH DESIGN; SAFETY; STEM CELL TRANSPLANTATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 77954916913     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/j.1748-720X.2010.00486.x     Document Type: Conference Paper

References (53)

1. Soldner F, Hockemeyer D. " Parkinson's Disease Patient-Derived Induced Pluripotent Stem Cells Free of Viral Reprogramming Factors," Cell 2009, 136(no. 5):964-77.
2. Dresser R. When Science Offers Salvation: Patient Advocacy and Research Ethics 2001, New York, Oxford University Press
3. Amariglio N, Hirshberg A. " Donor-Derived Brain Tumor Following Neural Stem Cell Transplantation in an Ataxia Telangiectasia Patient," PLoS Medicine 2009, 6(no. 2):e1000029.
4. Hyun I, Lindvall O. " New Isscr Guidelines Underscore Major Principles for Responsible Translational Stem Cell Research," Cell Stem Cell 2008, 3(no. 6):607-9. B. Lo, A. Kriegstein, and D. Grady, " Clinical Trials in Stem Cell Transplantation: Guidelines for Scientific and Ethical Review," 5, no. 5 (2008): 517-22; D. J. Mathews and J. Sugarman et al., " Cell-Based Interventions for Neurologic Conditions: Ethical Challenges for Early Human Trials," 71, no. 4 (2008): 288-293.
5. Poewe W. " Treatments for Parkinson Disease - Past Achievements and Current Clinical Needs," Neurology 2009, 72(no. 7):S65-S73. Supp.
6. Benabid A L, Chabardes S, Mitrofanis J, Pollak P. " Deep Brain Stimulation of the Subthalamic Nucleus for the Treatment of Parkinson's Disease," Lancet Neurology 2009, 8(no. 1):67-81. F. M. Weaver and K. Follett et al., " Bilateral Deep Brain Stimulation vs. Best Medical Therapy for Patients with Advanced Parkinson Disease: A Randomized Controlled Trial," 301, no. 1 (2009): 63-73.
7. Freed C R, Greene P E. " Transplantation of Embryonic Dopamine Neurons for Severe Parkinson's Disease," N. Engl. J. Med. 2001, 344(no. 10):710-9. C. W. Olanow, C. G. Goetz, et. al., " A Double-Blind Controlled Trial of Bilateral Fetal Nigral Transplantation in Parkinson's Disease," 54, no. 3 (2003): 403-14.
8. Braak H, Del Tredici K. " Assessing Fetal Nerve Cell Grafts in Parkinson's Disease," Nature Medicine 2008, 14(no. 5):483-485. J. H. Kordower and Y. Chu et al., " Lewy Body-Like Pathology in Long-Term Embryonic Nigral Transplants in Parkinson's Disease," 14, no. 5 (2008): 504-506; J. Y. Li and E. Englund et al., " Lewy Bodies in Grafted Neurons in Subjects with Parkinson's Disease Suggest Host-to-Graft Disease Propagation," 14, no. 5 (2008): 501-503; I. Mendez and A. Vinuela et al., " Dopamine Neurons Implanted into People with Parkinson's Disease Survive without Pathology for 14 Years," 14, no. 5 (2008): 507-509
9. Bodeen C, Zagier A S. " China Offers Unproven Medical Treatments,": San Francisco Chronicle. January 6 2008, A17. M. Enserink, " Selling the Stem Cell Dream," 313, no. 5784 (2006): 160-163; T. V. Padma, " Unchecked by Guidelines, Indian Stem Cell Scientists Rush Ahead," 12, no. 1 (2006): 4
10. Dobkin B H, Curt A, Guest J. " Cellular Transplants in China: Observational Study from the Largest Human Experiment in Chronic Spinal Cord Injury," Neurorehabilitation & Neural Repair 2006, 20(no. 1):5-13.
11. See Freed, at note 7.
12. " Cioms International Ethical Guidelines for Biomedical Research Involving Human Subjects, Revised Draft," http://www.cioms.ch/frame_guidelines_january_2002.htm,http://www.wma.net /e/ethicsunit/helsinki.htm, Council for International Organizations of Medical Sciences, , last visited April 5, 2010); National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, (Washington, D.C.: U.S. Government Printing Office, 1979); World Medical Association, " Declaration of Helsinki," , last visited April 5, 2010
13. http://www.hhs.gov/ohrp/humansubjects/guidance/45cfr46.htm, Protection of Human Subjects, 45 Cfr 46 (2005),, last visited April 5, 2010
14. Lo B. Ethical Dilemmas in Clinical Research: A Practical Guide 2009, Philadelphia, Lippincott Williams & Wilkins
15. Joffe S, Cook E F. " Quality of Informed Consent in Cancer Clinical Trials: A Cross-Sectional Survey," Lancet 2001, 358(no. 9295):1772-1777.
16. Appelbaum P S, Lidz C W. " The Therapeutic Misconception," The Oxford Textbook of Clinical Research Ethics 2008, 633-644. Emanuel E J, New York, Oxford University Press, C. W. Lidz, P. S. Appelbaum, T. Grisso, and M. Renaud, " Therapeutic Misconception and the Appreciation of Risks in Clinical Trials," 58, no. 9 (2004): 1689-1697.
17. Henderson G E, Davis A M. " Uncertain Benefit: Investigators' Views and Communications in Early Phase Gene Transfer Trials," Molecular Therapy 2004, 10(no. 2):225-31.
18. See Lo, note 16.
19. See Weaver, 2009; Benabid, 2009, note 6.
20. See Lo, note 16.
21. Horng S H, Miller F G. " Placebo-Controlled Procedural Trials for Neurological Conditions," Neurotherapeutics 2007, 4(no. 3):531-6.
22. Macklin R. " The Ethical Problems with Sham Surgery in Clinical Research," New England Journal of Medicine 1999, 341(no. 13):992-6.
23. See Horng, note 25.
24. Kim S Y, Frank S. " Science and Ethics of Sham Surgery: A Survey of Parkinson Disease Clinical Researchers," Archives of Neurology 2005, 62(no. 9):1357-1360.
25. Frank S A, Wilson R. " Ethics of Sham Surgery: Perspective of Patients," Movement Disorders 2008, 23(no. 1):63-68.
26. See Weaver, 2009 and Benabid, 2009, note 6.
27. Fleming T R, Prentice R L, Pepe M S, Glidden D. " Surrogate and Auxiliary Endpoints in Clinical Trials, with Potential Applications in Cancer and Aids Research." Statistics in Medicine 1994, 13:955-68.
28. See Freed, note 7.
29. Arkin L M, Sondhi D. " Confronting the Issues of Therapeutic Misconception, Enrollment Decisions, and Personal Motives in Genetic Medicine-Based Clinical Research Studies for Fatal Disorders," Human Gene Therapy 2005, 16(no. 9):1028-1036.
30. See Lo, note 4.
31. Lindvall O, Kokaia Z. " Prospects of Stem Cell Therapy for Replacing Dopamine Neurons in Parkinson's Disease," Trends in Pharmacological Sciences 2009, 30(no. 5):260-267.
32. Responsible Research: A Systems Approach to Protecting Research Participants 2003, Institute of Medicine, Washington, D.C., National Academies Press
33. " Guidelines for Human Embryonic Stem Cell Research," http://books.nap.edu/catalog.php?record_id=11278, National Academy of Sciences, National Academy Press, , last visited April 5, 2010
34. " Notice of Actions under the Nih Guidelines for Rsearch Involving Recombinant DNA Molecules," Federal Register 2000, 65:60627-332. National Institutes of Health
35. Scharschmidt T, Lo B. " Clinical Trial Design Issues Raised During Recombinant DNA Advisory Committee Review of Gene Transfer Protocols," Human Gene Therapy 2006, 17(no. 4):448-454.
36. " The Central Institutional Review Board Initiative," http://www.ncicirb.org/, National Cancer Institute, , last visited April 5, 2010
37. http://www.brany.com/, http://www.med.upenn.edu/ohr/aboutmacro.html, Biomedical Research Alliance of New York, , last visited April 5, 2010); Multicenter Academic Centers Research Organization,, last visited April 5, 2010
38. Tully S. " The Party's Over,": Fortune. June 26 2000, 156.
39. Steinbrook R. " The Gelsinger Case," 110-120. in Emanuel, note 18, at
40. See Lo, note 4.
41. Berg J W, Lidz C W, Appelbaum P S. Informed Consent: Legal Theory and Clinical Practice 2001, 2nd ed., New York, Oxford University Press
42. See Lo, note 4.
43. Woodsong C, Karim Q A. " A Model Designed to Enhance Informed Consent: Experiences from the Hiv Prevention Trials Network," American Journal of Public Health 2005, 95(no. 3):412-9.
44. Ethical and Policy Issues in Research Involving Human Participants 2001, National Bioethics Advisory Commission, Rockville, MD, National Bioethics Advisory Commission
45. See Hyun, 2007 and Lo, 2008, note 4.
46. See Steinbrook, note 43; J. Couzin and J. Kaiser, " Gene Therapy: As Gelsinger Case Ends, Gene Therapy Suffers Another Blow," 307, no. 5712 (2005): 1028; R. C. Fox and J. P. Swazey, (New York: Oxford University Press, 1992)
47. Lo B, Field MJ. Conflicts of Interest in Medical Research, Education, and Clinical Practice 2009, Washington, D.C., National Academies Press
48. Wood A J. " Progress and Deficiencies in the Registration of Clinical Trials." N. Engl. J. Med. 2009, 360(no. 8):824-30.